Tag Archives: BioSante Pharmaceuticals

Dendreon (NASDAQ:DNDN) Slashes 600 Jobs to Lower Costs – DNDN, BPAX, NLNK, PPHM

Posted on July 31, 2012 by Thomas Vedder

The Seattle-based Dendreon Corporation (NASDAQ:DNDN), manufacturer of the prostate cancer medicine Provenge, reported that it would remove over 600 jobs and lower costs by $150 million during the coming 12 months as it looks to reach profitability.

Dendreon reported in …

Posted in Healthcare, Latest Headlines | Tagged BioSante Pharmaceuticals, BPAX, Dendreon, DNDN, NASDAQ:BPAX, NASDAQ:DNDN, NASDAQ:NLNK, NASDAQ:PPHM, NewLink, NLNK, Peregrine, PPHM | Comments Off

Arena (NASDAQ:ARNA) Climbs Around 74% Green Mountain on Advisory Panel’s Decision- ARNA, VVUS, DNDN, OREX, HGSI, BPAX, KERX,

Posted on May 14, 2012 by Geoff Noir

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) jumped around 74 percent. The moved up followed a Food and Drug Administration advisory panel’s decision, in an 18-to-4 vote, to back authorization of teh weight-loss treatment lorcaserin.

The panel’s decision came as accessible data demonstrate …

Posted in Healthcare, Latest Headlines | Tagged Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Dendreon, DNDN, HGSI, Human Genome Sciences, KERX, Keryx Biopharmaceuticals, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:DNDN, NASDAQ:HGSI, NASDAQ:KERX, NASDAQ:OREX, NASDAQ:VVUS, OREX, Orexigen Therapeutics, Vivus, VVUS | Comments Off

Novavax (NASDAQ:NVAX) Shares Surges on Healthy Results- NVAX, KERX, DNDN, ARNA, BPAX, AEZS, CTIC

Posted on May 7, 2012 by Geoff Noir

Novavax Inc (NASDAQ:NVAX) shares climbed 2.22 percent to $1.38 following the firm posted Q1 results. Net loss was $7.3 million or $0.06 a share evaluated with net loss of $7.5 million or $0.07 a share in the Q1 of 2011. …

Posted in Latest Headlines | Tagged AEterna Zentaris, AEZS, Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Cell Therapeutics, CTIC, Dendreon, DNDN, KERX, Keryx Biopharmaceuticals, NASDAQ:AEZS, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:CTIC, NASDAQ:DNDN, NASDAQ:KERX, NASDAQ:NVAX, Novavax, NVAX | Comments Off

Healthcare Giant GlaxoSmithKline (NYSE:GSK) Bid on Human Genome Sciences- HGSI, GSK, HGSI, DNDN, ARNA, KERX, BPAX, VVUS, AEZS

Posted on April 20, 2012 by Geoff Noir

Biotech drug maker Human Genome Sciences (NASDAQ:HGSI) has refused an unwanted $2.59 billion acquisition bid by GlaxoSmithKline (NYSE:GSK), the British pharmaceutical giant that spent almost 20 years helping the smaller firms bring its first drug to market.

Rockville, Md.-based …

Posted in Healthcare, Latest Headlines | Tagged AEterna Zentaris, AEZS, Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Dendreon, DNDN, HGSI, Human Genome Sciences, KERX, Keryx Biopharmaceuticals, NASDAQ:AEZS, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:DNDN, NASDAQ:HGSI, NASDAQ:KERX, NASDAQ:VVUS, Vivus, VVUS | Comments Off

3 stocks to watch on Wednesday (BPAX, ACAS, RENN)

Posted on February 14, 2012 by Thomas Vedder

In this report: BioSante Pharmaceuticals (NASDAQ:BPAX), American Capital (NASDAQ:ACAS) and Renren (NASDAQ:RENN).

BioSante Pharmaceuticals (NASDAQ:BPAX) share have soared by more than 44 percent in after hours trading. The rally comes after a day which seen investors in a selling spree …

Posted in Latest Headlines, Reports | Tagged ACAS, American Capital, BioSante Pharmaceuticals, BPAX, NASDAQ:ACAS, NASDAQ:BPAX, NASDAQ:RENN, RENN, Renren | Comments Off

BioSante Pharmaceuticals Looks Ahead, Releases Promising Results

Posted on February 9, 2012 by admin

In a press release put out by BioSante Pharmaceuticals (NASDAQ:BPAX) this morning, the company reported that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of …

Posted in Healthcare, Reports | Tagged BioSante Pharmaceuticals, BPAX, FDA, LiBiGel, NASDAQ:BPAX | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.